Cure My Disease

Don't miss your cure!

 Log in / Sign up

New pill aims to stall advanced prostate cancer when hormone drugs fail

NCT ID NCT06636123

Recruiting now Disease control Sponsor: Virginia Commonwealth University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase trial tests an oral drug called GZ17-6.02 in 30 men with castration-resistant prostate cancer that has progressed after standard hormone therapy. The goal is to see if the drug can delay cancer growth for at least 6 months. Participants take the drug twice daily with a high-fat meal until the cancer worsens or side effects become too severe.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
GZ17-6.02
What this could lead to
If it works, this could offer a new oral option to delay cancer progression in men with advanced prostate cancer who have stopped responding to standard hormone therapies.
What could go wrong
This is a very early Phase 1 trial with only 30 participants, so it is too soon to know if GZ17-6.02 is effective or safe. Many early-stage drugs do not succeed in larger studies.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CASTRATION-RESISTANT PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

castration-resistant prostate carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CASTRATION-RESISTANT PROSTATE CANCER

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Virginia Commonwealth University

    RECRUITING

    Richmond, Virginia, 23298, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.